592998 Disclosed herein is a depot formulation comprising as active ingredient octreotide, or a pharmaceutically acceptable salt thereof, and two linear polylactide-co-glycolide polymers (PLGAs) and having a molar lactide:glycolide (L:G) ratio of 75:25 and different inherent viscosities； and the use thereof for the treatment of a disease selected from long-term maintenance therapy in acromegalic patients, and treatment of severe diarrhoea and flushing associated with malignant carcinoid tumours and vasoactive intestinal peptide tumours (vipoma tumours). In one embodiment wherein said polymers have different inherent viscosities between 0.8 and 0.1 dL/g in CHCl3. In one embodiment wherein said two polymers have different end groups, particularly wherein one polymer has an ester and the other polymer has an acid end group.
